Senate Panel Plans Looser Rules On Pay-For-Delay

Law360, New York (September 24, 2009, 4:46 PM EDT) -- The U.S. Senate Judiciary Committee is considering creating provisions in proposed legislation to allow pharmaceutical companies to forge deals delaying the market debut of generic drugs, if those deals present “clear and convincing evidence” of pro-competitive benefits.

During a mark-up session Thursday, the Senate Judiciary Committee adopted by unanimous consent changes to S. 369, the Preserve Access to Affordable Generics Act, submitted by Sen. Herb Kohl, D-Wis., which back away from the original bill's intent to ban any agreement between pharmaceutical companies to keep new generic...
To view the full article, register now.